Michael Huang serves as Independent Director of the Company. Mr. Huang serves as Managing Partner at Taiwania Capital Management Corporation, a venture capital firm. From 2014 to 2017, Mr. Huang served as Chief Executive Officer of NeuroVive Pharmaceutical Asia, Inc., a biopharmaceutical company. Mr. Huang holds an MBA from Rice University, a M.A. in Chemistry from the University of Texas, Arlington, and a B.S. from University of Texas, Austin.
As the Independent Director of Frequency Therapeutics Inc, the total compensation of Michael Huang at Frequency Therapeutics Inc is $94,463. There are 9 executives at Frequency Therapeutics Inc getting paid more, with David Lucchino having the highest compensation of $7,364,600.
Michael Huang is 46, he's been the Independent Director of Frequency Therapeutics Inc since 2018. There are 15 older and 2 younger executives at Frequency Therapeutics Inc. The oldest executive at Frequency Therapeutics Inc is Timothy Barberich, 72, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O FREQUENCY THERAPEUTICS, INC.,, 75 HAYDEN AVE, SUITE 300, LEXINGTON, MA, 02421.
Over the last 5 years, insiders at Frequency Therapeutics Inc have traded over $11,017,122 worth of Frequency Therapeutics Inc stock and bought 369,233 units worth $5,339,982 . The most active insiders traders include Joel S Marcus, Robert Langer et Marc A Cohen. On average, Frequency Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,858. The most recent stock trade was executed by Richard J. Mitrano on 18 August 2023, trading 464 units of FREQ stock currently worth $269.
frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the complexity of genetic engineering. our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the u.s. alone.
Frequency Therapeutics Inc executives and other stock owners filed with the SEC include: